2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1355

Ankle Periarthritis, a New Sign for Chikungunya : Ultrasound Study of Joint Lesions at the Acute Phase of Chikungunya
Abstract Number: 2377

Anti 3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase in Systremic Sclerosis
Abstract Number: 73

Anti -N-Methyl-D-Aspartate Receptor Antibody Is Associated with Fibromyalgia in Patients with Systemic Lupus Erythematosus
Abstract Number: 2433

Anti Interferon-Gamma (IFNg) Monoclonal Antibody Treatment in a Child with NLRC4-Related Disease and Severe Hemophagocytic Lymphohistiocytosis (HLH)
Abstract Number: 2456

Anti SRP+Ve Myositis in Childhood. Presentation and Physiotherapy Treatment of This Rare Childhood Myositis
Abstract Number: 2364

Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase Positive Myopathy Patients without Statin Exposure May Have a Progressive Disease That Worsens Despite Aggressive Immunosuppressive Therapy
Abstract Number: 3045

Anti-Alpha-Enolase Antibodies in Behçet’s Disease: A Marker of Articular Disease Activity?
Abstract Number: 405

Anti-C1q Antibodies As Potential Diagnostic and Prognostic Biomarkers in Juvenile Systemic Lupus Erythematosus
Abstract Number: 786

Anti-Carbamylated Protein Antibodies Identify Systemic Lupus Erythematosus Patients with Erosive Arthritis: Analysis of a Regional Swedish Register
Abstract Number: 152

Anti-CCP Positive Patients without Clinical Synovitis Progress If Ultrasound Positive
Abstract Number: 633

Anti-Centromere Antibodies Are Associated with More Severe Exocrine Glandular Dysfunction in Primary Sjögren’s Syndrome: An Analysis of the Sjögren’s International Collaborative Clinical Alliance Cohort
Abstract Number: 2590

Anti-Citrullinated Protein Antibody and Radiographic Disease Progression in Rheumatoid Arthritis
Abstract Number: 1740

Anti-Cyclic Citrullinated Peptide Antibodies and Inflammatory Bowel Disease
Abstract Number: 2607

Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Rheumatoid Arthritis Hispanics Exposed to Biomass Smoke
Abstract Number: 1463

Anti-Cyclic Citrullinated Peptide Antibody Subclass Phenotypes in Polyarticular Juvenile Idiopathic Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].